EUR 18.38
(0.33%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 539.32 Million EUR | -4.1% |
2022 | 562.37 Million EUR | 18.41% |
2021 | 474.95 Million EUR | -4.05% |
2020 | 495 Million EUR | -10.78% |
2019 | 554.79 Million EUR | 17.28% |
2018 | 473.05 Million EUR | 15.61% |
2017 | 409.16 Million EUR | -42.79% |
2016 | 715.17 Million EUR | -5.17% |
2015 | 754.15 Million EUR | -7.67% |
2014 | 816.8 Million EUR | 25.75% |
2013 | 649.52 Million EUR | 29.0% |
2012 | 503.51 Million EUR | 9.51% |
2011 | 459.78 Million EUR | 25.81% |
2010 | 365.47 Million EUR | 32.51% |
2009 | 275.8 Million EUR | 18.78% |
2008 | 232.2 Million EUR | 37.2% |
2007 | 169.24 Million EUR | -11.19% |
2006 | 190.57 Million EUR | 0.74% |
2005 | 189.17 Million EUR | 10.85% |
2004 | 170.65 Million EUR | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q2 | 567.94 Million EUR | 0.0% |
2023 Q2 | 584.19 Million EUR | 0.0% |
2023 FY | 539.32 Million EUR | -4.1% |
2023 Q4 | 539.32 Million EUR | 0.0% |
2022 FY | 562.37 Million EUR | 18.41% |
2022 Q4 | 562.37 Million EUR | 0.0% |
2022 Q2 | 581.49 Million EUR | 0.0% |
2021 Q2 | 502.54 Million EUR | 0.0% |
2021 Q4 | 474.95 Million EUR | 0.0% |
2021 FY | 474.95 Million EUR | -4.05% |
2020 Q2 | 579.62 Million EUR | 0.0% |
2020 Q4 | 495 Million EUR | 0.0% |
2020 FY | 495 Million EUR | -10.78% |
2019 Q2 | 548.22 Million EUR | 0.0% |
2019 Q4 | 554.79 Million EUR | 0.0% |
2019 FY | 554.79 Million EUR | 17.28% |
2018 FY | 473.05 Million EUR | 15.61% |
2018 Q4 | 473.05 Million EUR | 0.0% |
2018 Q2 | 495.97 Million EUR | 0.0% |
2017 FY | 409.16 Million EUR | -42.79% |
2017 Q4 | 409.16 Million EUR | 0.0% |
2017 Q2 | 667.87 Million EUR | 0.0% |
2016 FY | 715.17 Million EUR | -5.17% |
2016 Q4 | 715.17 Million EUR | 0.0% |
2016 Q2 | 710.12 Million EUR | 0.0% |
2015 FY | 754.15 Million EUR | -7.67% |
2015 Q4 | 754.15 Million EUR | 0.0% |
2015 Q2 | 772.39 Million EUR | 0.0% |
2014 Q2 | 821.8 Million EUR | 0.0% |
2014 FY | 816.8 Million EUR | 25.75% |
2014 Q4 | 816.8 Million EUR | 0.0% |
2013 Q4 | 649.52 Million EUR | 0.0% |
2013 FY | 649.52 Million EUR | 29.0% |
2013 Q2 | 623.31 Million EUR | 0.0% |
2012 Q2 | 464.42 Million EUR | 0.0% |
2012 Q4 | 503.51 Million EUR | 0.0% |
2012 FY | 503.51 Million EUR | 9.51% |
2011 FY | 459.78 Million EUR | 25.81% |
2011 Q2 | 385.05 Million EUR | 0.0% |
2011 Q4 | 459.78 Million EUR | 0.0% |
2010 Q2 | 297.17 Million EUR | 0.0% |
2010 Q4 | 365.47 Million EUR | 0.0% |
2010 FY | 365.47 Million EUR | 32.51% |
2009 FY | 275.8 Million EUR | 18.78% |
2009 Q4 | 275.8 Million EUR | 0.0% |
2008 FY | 232.2 Million EUR | 37.2% |
2007 FY | 169.24 Million EUR | -11.19% |
2006 FY | 190.57 Million EUR | 0.74% |
2005 FY | 189.17 Million EUR | 10.85% |
2004 FY | 170.65 Million EUR | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
AB Science S.A. | 46.5 Million EUR | -1059.646% |
Boiron SA | 198.7 Million EUR | -171.427% |
Ipsen S.A. | 2.49 Billion EUR | 78.418% |
Malin Corporation plc | 7.1 Million EUR | -7496.169% |
Vetoquinol SA | 165.12 Million EUR | -226.624% |